Novartis Pharms. Corp. v. Mylan Pharms. Inc. – Entresto® (Sacubitril/Valsartan)

May 17, 2024

Case Name: Novartis Pharms. Corp. v. Mylan Pharms. Inc., Civ. No. 19-cv-201, 2024 WL 384929 (N.D.W.V. Jan. 31, 2024) (Kleeh, J.) – Drug Product and Patent(s)-in-Suit: Entresto® (sacubitril/valsartan); U.S. Patents Nos. 8,877,938 (“the ’938 patent”) and 9,388,134 (“the ’134 patent”)….
By: Robins Kaplan LLP

Novartis Pharms. Corp. v. Mylan Pharms. Inc. – Entresto® (Sacubitril/Valsartan)

Enhancing Trade-Based Money Laundering Detection: Retrieval-Augmented Generation and Semantic Search Technologies

New Legislation Would Establish the First US National Comprehensive Privacy Law